Biodegradable Matrix Eluting CXCL12 for Beta Cell Immune Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for implanting beta cells in diabetic patients face challenges such as low survival rates due to immune rejection and the need for frequent surgeries to replace biodegradable matrices, which are inconvenient and risky, and genetically modified cells lack immune protection upon implantation.
Innovation Solution
Implanting genetically engineered mammalian cells, such as human beta cells, with a rapidly biodegradable matrix impregnated with a fugetactic agent like CXCL12 to provide initial immune protection during the implantation period, allowing the cells to establish their own protective microenvironment and integrate effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a biodegradable matrix is used to protect implanted beta cells, then immune protection is provided during implantation, but the matrix requires frequent replacement surgeries when its useful life is exhausted
Solution Approach 1:
The fugetactic agent is pre-loaded into the biodegradable matrix before implantation, providing immediate immune protection from the moment of implantation. This preliminary preparation eliminates the need for post-implantation immune suppression and ensures continuous protection throughout the matrix's degradation period, resolving the contradiction between providing reliable immune protection and avoiding frequent replacement surgeries.
2Duration of action of stationary object
If the fugetactic agent is eluted from the matrix over an extended period, then immune protection is maintained, but the elution effectiveness varies between patients and is limited in duration
Solution Approach 1:
The invention optimizes the parameters of the biodegradable matrix, including its degradation rate, porosity, and fugetactic agent loading concentration, to ensure consistent and reliable elution over an extended period. By carefully controlling these parameters, the matrix provides predictable immune protection that lasts throughout its useful life, resolving the contradiction between maintaining prolonged protection and ensuring reliable elution effectiveness across different patients.
3Reliability
If genetically modified beta cells express a fugetactic agent, then immune protection is generated in vitro, but the protective microenvironment is not maintained upon implantation in vivo
Solution Approach 1:
The biodegradable matrix serves as an intermediary between the genetically modified beta cells and the host immune system. It provides a controlled microenvironment that maintains fugetactic agent concentration gradients, protecting the cells during the critical transition from in vitro to in vivo conditions. This intermediary support ensures the stability of the protective microenvironment until the cells can fully establish themselves in the host, resolving the contradiction between generating immune protection and maintaining microenvironment stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the survival and functionality of implanted beta cells by providing immediate immune protection and allowing them to regenerate their own protective environment, reducing the risk of immune attack and the need for frequent surgeries.
Implementation Method 1
the matrix is impregnated with fugetactic agent that elutes a sufficient amount over an extended period of time so as to provide immune protection to the encapsulated cells
Implementation Method 2
Implanting genetically engineered mammalian cells, such as human beta cells, with a rapidly biodegradable matrix
Data Source
AI summary
Described herein are compositions and methods for treating a subject having diabetes comprising administering transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Genetically engineered immune-protected, human beta cells are also described. The disclosed engineered beta cells can be administered to the subject alone or implanted into or with a biocompatible and biodegradable matrix that elutes an effective amount of a fugetactic agent, which is then implanted into the subject.